Multiplex targeted high-throughput sequencing in a series of 352 patients with congenital limb malformations.
Anne-Sophie JourdainFlorence PetitMarie-Françoise OdouMalika BalduyckPerrine BrunelleWilliam DufourSimon BoussionElise Brischoux-BoucherCindy ColsonAnne DieuxMarion GérardJamal GhoumidFabienne GiulianoAlice GoldenbergPhilippe Khau Van KienDaphné LehalleGilles MorinSébastien MouttonThomas SmolClémence VanlerbergheSylvie Manouvrier-HanuFabienne EscandePublished in: Human mutation (2019)
Congenital limb malformations (CLM) comprise many conditions affecting limbs and more than 150 associated genes have been reported. Due to this large heterogeneity, a high proportion of patients remains without a molecular diagnosis. In the last two decades, advances in high throughput sequencing have allowed new methodological strategies in clinical practice. Herein, we report the screening of 52 genes/regulatory sequences by multiplex high-throughput targeted sequencing, in a series of 352 patients affected with various CLM, over a 3-year period of time. Patients underwent a clinical triage by expert geneticists in CLM. A definitive diagnosis was achieved in 35.2% of patients, the yield varying considerably, depending on the phenotype. We identified 112 single nucleotide variants and 26 copy-number variations, of which 52 are novel pathogenic or likely pathogenic variants. In 6% of patients, variants of uncertain significance have been found in good candidate genes. We showed that multiplex targeted high-throughput sequencing works as an efficient and cost-effective tool in clinical practice for molecular diagnosis of congenital limb malformations. Careful clinical evaluation of patients may maximize the yield of CLM panel testing.